Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

AlphaOne enters agreement with Dana-Farber for tumor suppressor gene

July 12, 2000

Maxim licenses caspase-activating anticancer compounds to BioChem Pharma

July 11, 2000

Tumor antigen-specific chimeric proteins from Idec promote antitumor immune response

July 11, 2000

Shortened Taxol regimen approved by FDA for advanced ovarian cancer

July 11, 2000

Chemoprotective effects of KF-41399 demonstrated in nimustine-treated mice

July 11, 2000

New benzazepine selectively targets tumor cells and induces G2/M arrest and apoptosis

July 11, 2000

Angiostatin combined with radiation therapy enters phase I trials

July 11, 2000

SkyePharma grants Paladin exclusive Canadian rights for DepoCyt

July 10, 2000

Aronex files NDA amendment for Atragen as treatment for APL

July 10, 2000

Abbott licenses novel antimitotic agent from Eisai

July 10, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...